Cimivir L Tablets

210.00$ 190.00$



Sofosbuvir for 60 mg and Ledipasvir for 90 mg – 28 tablets

Manufacturer – Biocon India

Biocon, an Indian biopharmaceutical company, produces the drug Cimivir-L, which is a generic form of the known antiviral drug Harvoni from the American firm Gilead. It is a combination of two known drugs, Sofosbuvir and Ledipasvir, with a fixed dose of 400 and 90 mg, respectively. The drug is intended for the treatment of patients infected with the hepatitis C virus of the first genotype.

Instructions for use

It is a combination of 2 hepatitis C virus (HCV) antiviral agents. This reduces the amount of hepatitis C virus in the body by preventing the spread of the hepatitis virus in the body.

The drug is produced by the Indian company Biocon. Its cost, for example, in German pharmacies is 650 euros. While there is a possibility of international delivery to Russia from India at a price of $ 310. for packing, i. 930 dollars. for a 12-week course.

Description of the preparation

Ledipasvir was developed by the American company Gilead Sciences. Previously, this substance was called GS-5885. The effect of this drug is aimed at inhibiting the replication processes of non-structural proteins.

Let’s take a closer look at the mechanism of the action of Ladypasvira. It is known that the structure of the hepatitis C virus (HCV) is quite complex and multifaceted. The established forms of HCV are dangerous in that, with many years of development, new cells appear in the body, mutated, which have other antigenic properties.

That is why the immune system of an infected person is not able to cope with them on its own: while antibodies to one kind of cells are being developed, new ones are appearing. In this regard, it makes sense to use blockers of those structural elements of the virus, which are responsible for the replication of the latter. Such an element is NS5A. A blocker, i.e. inhibitor, advocated by Ledipasvir, which prevents further reproduction of HCV.

A special feature of the Ledipasvir product is that it does not act as an independent drug that can heal people from hepatitis C and until recent years has not been introduced to the pharmaceutical market. Without fail, GS-5885 is used in conjunction with other drugs that fight with viruses.

The most famous and effective is the combination of Ledipasvir and Sofosbuvir. A study of the efficacy and safety of this combination with the addition of Ribavirin, as well as without it for the treatment of the 1 hepatitis C genotype at different stages of the disease, was conducted within the framework of 3 clinical trials.

Patients with different initial data in the amount of about 2000 people took part in the studies. All participants were divided into subgroups, taking into account the degree of fibrosis, previous results of therapy, if such was conducted.

By results, it became clear that a 12-week course of a combination of three drugs leads to a stable virologic response in 100% of cases. However, the results of therapy with the “duet” Ladipasvira with Sofosbuvir, conducted in other subgroups, were not very different in the degree of effectiveness, their rate was 94-95%. Therefore, Gilead Sciences decided to patent a complex of the two mentioned components without Ribavirin. The trade name of this drug was called Harvoni.

Studies have also shown that treatment with Ledipasvir in combination with Sofosbuvir almost does not cause side effects. The most common adverse effects of such therapy were a headache and fatigue, a slight drowsiness. It is noteworthy that with the triple therapy of Harvoni with Ribavirin, undesirable effects were more frequent.

Features of the appointment

Before appointing the drug, the attending physician must conduct appropriate studies to correctly take into account the patient’s body condition and compare the results of the examination with indications for use and existing contraindications. Because Ledipasvir is not used as an independent medicinal product but combined with other substances, and the features of the appointment are associated with the properties of all components in the complex. We describe them.

Complex diagnostics should be carried out without fail. A biopsy of liver tissue or elastography is aimed at determining the structure of the organ and the degree of fibrosis of the tissues. An alternative method of biopsy and elastography is fibrotest, which is performed after the mathematical treatment of important blood parameters (haptoglobin, alpha2-macroglobulin, gamma-glutamyltransferase, apolipoprotein A1, alanine aminotransferase and total bilirubin). Fibrotest is able to show not only the stage of liver fibrosis but also the level of activity of the necro-inflammatory process. The data of such testing are easily interpreted by medical specialists all over the world.

The approved dosage of the drug components in one Harvoni tablet is as follows: Ledipasvir in a volume of 90 mg, and Sofosbuvir is 400 mg. Magnesium stearate and lactose monohydrate are used as additional ingredients.

The scheme of treatment is quite simple: one tablet a day without binding to food intake, but it is not advisable to drink the medicine on an empty stomach. The duration of the course is determined by the doctor. The minimum rate is 12 weeks. If necessary, the terms are increased in two. However, if there are no noticeable improvements in the viral load at 8-12 weeks, the drug is likely to be canceled due to inefficiency.

In some cases, based on preliminary studies, the doctor may recommend the addition of ribavirin to therapy.

Thanks to the production of Ledipasvir analogs, patients’ reviews are not burdened by discontent with high prices and are only positive.


There are no reviews yet.

Be the first to review “Cimivir L Tablets”

Your email address will not be published. Required fields are marked *

Questions and answers of the customers

There are no questions yet, be the first to ask something for this product.